The Court of Appeal has ruled unanimously that a policy of offering bevacizumab (Avastin) off label to NHS patients with wet age-related macular degeneration (AMD) as an alternative to the much more expensive drugs ranibizumab (Lucentis) and aflibercept (Eylea) is lawful.1
In a major judgment with far reaching implications for the NHS and the drug industry, the three judges rejected arguments by the drug companies Novartis and Bayer that the policy breached EU law on medicines and UK legislation.
Twelve clinical commissioning groups in the north of England adopted a policy in 2017 that the NHS trusts providing services to them should offer patients a choice between bevacizumab, licensed as a cancer treatment but not …

中文翻译：

---

上诉法院称，为潮湿的AMD提供Avastin是合法的

上诉法院一致裁定，为患有湿性年龄相关性黄斑变性（AMD）的NHS患者提供贝伐单抗（Avastin）替代产品的政策是替代昂贵的兰尼单抗（Lucentis）和aflibercept（Eylea）的替代品合法的 1
在一项对国民健康服务体系和药品行业具有深远影响的重大判决中，三名法官拒绝了诺华制药公司和拜耳公司关于该政策违反欧盟有关药品的法律和英国立法的论点。
英格兰北部的十二个临床调试小组于2017年通过了一项政策，即NHS信任向他们提供服务的患者应在贝伐单抗（已获许可用于癌症治疗）之间选择，而不能……